tiprankstipranks
Trending News
More News >
Tissue Regenix Group PLC (GB:TRX)
LSE:TRX

Tissue Regenix (TRX) Price & Analysis

Compare
14 Followers

TRX Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

0.77%99.23%
Mutual Funds
― Other Institutional Investors
99.23% Public Companies and
Individual Investors

TRX FAQ

What was Tissue Regenix Group PLC’s price range in the past 12 months?
Tissue Regenix Group PLC lowest share price was 0.28p and its highest was 0.75p in the past 12 months.
    What is Tissue Regenix Group PLC’s market cap?
    Tissue Regenix Group PLC’s market cap is £20.30M.
      When is Tissue Regenix Group PLC’s upcoming earnings report date?
      Tissue Regenix Group PLC’s upcoming earnings report date is Sep 03, 2025 which is in 56 days.
        How were Tissue Regenix Group PLC’s earnings last quarter?
        Tissue Regenix Group PLC released its earnings results on Jun 25, 2025. The company reported -0.005p earnings per share for the quarter, missing the consensus estimate of 0p by -0.005p.
          Is Tissue Regenix Group PLC overvalued?
          According to Wall Street analysts Tissue Regenix Group PLC’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Tissue Regenix Group PLC pay dividends?
            Tissue Regenix Group PLC does not currently pay dividends.
            What is Tissue Regenix Group PLC’s EPS estimate?
            Tissue Regenix Group PLC’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Tissue Regenix Group PLC have?
            Tissue Regenix Group PLC has 71,395,640 shares outstanding.
              What happened to Tissue Regenix Group PLC’s price movement after its last earnings report?
              Tissue Regenix Group PLC reported an EPS of -0.005p in its last earnings report, missing expectations of 0p. Following the earnings report the stock price went up 3.333%.
                Which hedge fund is a major shareholder of Tissue Regenix Group PLC?
                Currently, no hedge funds are holding shares in GB:TRX

                Tissue Regenix Stock Smart Score

                2
                Underperform
                1
                2
                3
                4
                5
                6
                7
                8
                9
                10

                Technicals

                SMA
                Negative
                20 days / 200 days
                Momentum
                -56.81%
                12-Months-Change

                Fundamentals

                Return on Equity
                -2.91%
                Trailing 12-Months
                Asset Growth
                6.74%
                Trailing 12-Months

                Company Description

                Tissue Regenix Group PLC

                Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine in the United States and internationally. It operates through BioSurgery, Orthopaedics & Dental, and GBM-V & Cardiac divisions. The company provides dCELL technology, a soft tissue decellularisation process that removes DNA and cellular material from animal and human soft tissue to repair diseased or damaged body parts; and BioRinse technology, a natural bone filler solution for osteoinductive to stimulate and regenerate native bone growth. In addition, the company provides DermaPure, a decellularised dermal allograft for reinforcement, repair, and replacement of damaged or inadequate integumental tissue and other homologous uses of human integument; and SurgiPure XD, Decellularised porcine dermal reconstructive tissue matrix for the repair of hernias and body wall defects. Further, it offers OrthoPure XT, a scaffold to replace the damaged tissue that will re-populate with the patient's own cells; ConCelltrate 100, a verified osteoinductive bone matrix; MatrixCellect 100, a demineralised bone matrix (DBM) for orthopaedic; Matrix IQ Dermis, a human-derived dermal graft, which is decellularised to remove cellular components and preserve the biological properties that promote revascularisation, repair, and augmentation of damaged tissue; and Matrix OI FlexIt, a thin pliable demineralised cortical allograft bone sheet. Additionally, the company provides DentalFix, a mineralized particulate allograft that offer osteoconductive properties of natural bone; CardioPure products; Matrix OI 100 DBM for non-structural bone-grafting; Matrix OI Strips and Blocks, a stem cell containment human scaffold; AmnioWorks for ophthalmology and wound covering; and sports medicine products. The company was incorporated in 2006 and is based in Garforth, the United Kingdom.
                Similar Stocks
                Company
                Price & Change
                Follow
                Futura Medical
                ImmuPharma
                Oxford BioDynamics
                Sareum Holdings
                Arecor Therapeutics PLC
                Popular Stocks
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis